Hearing explores how drug companies stifle innovation, prioritize profits

The House Energy and Commerce Subcommittee on Consumer Protection and Commerce today held a to examine how pharmaceutical companies are putting 鈥減rofits over consumers,鈥 highlighting how profits made from drug sales are concentrated around only a few drugs with no competition. 鈥淭he bottom line is this: drug manufacturers are gaming the system to make more money at consumers鈥 expense,鈥 said Chairwoman Jan Schakowsky, D-Ill. 鈥淎nd that has to stop.鈥 Witnesses for the hearing were from Rutgers Institute for Information Policy and Law, Emory University School of Law, the Association for Accessible Medicines, and Patients for Affordable Drugs.
Related News Articles
Headline
The White House April 15 released an executive order directing federal agencies to undertake a broad range of tasks aimed at reducing the costs of prescription鈥
Headline
The Department of Commerce yesterday released notices announcing national security investigations on imports of pharmaceuticals, pharmaceutical ingredients and鈥
Headline
The AHA Feb. 28 filed a friend-of-the-court brief in the U.S. Court of Appeals for the 4th Circuit, urging the court to affirm a decision by the U.S. District鈥
Headline
Sens. Dick Durbin, D-Ill., and Chuck Grassley, R-Iowa, Jan. 23 introduced the Drug-price Transparency for Consumers Act, legislation supported by the AHA that鈥
Headline
The Department of Health and Human Services Jan. 17 announced 15 Medicare Part D drugs selected for the latest round of price negotiations. Negotiations will鈥
Headline
Prices for the top 25 brand-name Medicare Part D drugs have increased by an average of 98% since entering the market, according to a report released Jan. 9 by鈥